EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan

Ryotaro Ishii iD, Kei Ishizuchi, Narumi Watanabe, Ryosuke Fukazawa, Meesha Trivedi, Jin Nakahara, Tsubasa Takizawa

Cephalalgia · 2024-06 · 44 (6)

DOI: 10.1177/03331024241258695 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 11.06.2024. Verfasst von Ryotaro Ishii und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Migraine Disorders, Pyridines, Piperidines, Benzamides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world data on the effectiveness and safety of lasmiditan, a new medication for acute migraine attacks, is necessary.

Methods

We performed a prospective, observational, multi-center, real-world study. A total of 48 patients with migraine (44 females, 44.6 ± 12.9 years old) were included in this study.

Results

Twenty-three patients (47.9%) reported they were headache-free two hours after taking lasmiditan and were categorized into the responder group. In total, 44 patients (91.7%) experienced at least one side effect within two hours of taking the medication. Dizziness, somnolence, malaise, nausea, and palpitations were reported by 56.3% (n = 27), 45.8% (n = 22), 37.5% (n = 18), 20.8% (n = 10), and 14.6% (n = 7) of patients respectively. Of 48 patients, 20 (41.7%) indicated that they preferred lasmiditan to their previous acute treatment. There were no predictive factors for efficacy.

Conclusion

This real-world study demonstrated the efficacy and safety of lasmiditan. More than 90% of patients experienced side effects from lasmiditan. Approximately 40% of patients preferred lasmiditan despite the occurrence of side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersPyridinesPiperidinesBenzamidesHumansFemaleMaleAdultMiddle AgedJapanProspective StudiesTreatment OutcomeSerotonin Receptor Agonists

Stichwörter der Autor:innen

Japanefficacylasmiditanmigrainereal-world datatolerability

Substanzen

lasmiditanPyridinesPiperidinesBenzamidesSerotonin Receptor Agonists

Autor:innen und Institutionen

  • Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Neurology, Kyoto Okamoto Memorial Hospital, Kyoto, Japan.
  • Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Neurology, Saiseikai Shiga Hospital, Shiga, Japan.
  • Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.

ORCID-Profile: Ryotaro Ishii

Zitieren

APA

Ishii, R., Ishizuchi, K., Watanabe, N., Fukazawa, R., Trivedi, M., Nakahara, J., & Takizawa, T. (2024). Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan. Cephalalgia, 44(6). https://doi.org/10.1177/03331024241258695

Vancouver

Ishii R, Ishizuchi K, Watanabe N, Fukazawa R, Trivedi M, Nakahara J, et al. Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan. Cephalalgia. 2024;44(6). doi:10.1177/03331024241258695

BibTeX
@article{Ishii2024,
  author = {Ishii, Ryotaro and Ishizuchi, Kei and Watanabe, Narumi and Fukazawa, Ryosuke and Trivedi, Meesha and Nakahara, Jin and Takizawa, Tsubasa},
  title = {Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan},
  journal = {Cephalalgia},
  year = {2024},
  volume = {44},
  number = {6},
  doi = {10.1177/03331024241258695}
}
Kostenlos starten →